Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 374,874 |
|
|||||
| News | - | ||||||
| Day High | 3.57 | Low High |
|||||
| Day Low | 3.28 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Omeros Corporation | OMER | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.14 | 4.23% | 3.45 | 15:30:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.30 | 3.28 | 3.57 | 3.45 | 3.31 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,184 | 374,874 | US$ 3.36 | US$ 1,258,496 | - | 0.92 - 7.7975 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:30:11 | 1 | US$ 3.43 | USD |
Omeros Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 216.89M | 62.87M | - | 0 | -117.81M | -1.87 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Omeros News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OMER Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.59 | 4.34 | 3.0001 | 3.69 | 502,397 | -0.14 | -3.90% |
| 1 Month | 3.17 | 4.34 | 2.965 | 3.47 | 288,657 | 0.28 | 8.83% |
| 3 Months | 4.22 | 4.85 | 2.839 | 3.70 | 378,756 | -0.77 | -18.25% |
| 6 Months | 1.54 | 5.135 | 1.49 | 3.37 | 578,441 | 1.91 | 124.03% |
| 1 Year | 5.35 | 7.7975 | 0.92 | 3.61 | 618,685 | -1.90 | -35.51% |
| 3 Years | 18.08 | 18.35 | 0.92 | 5.48 | 776,718 | -14.63 | -80.92% |
| 5 Years | 18.90 | 25.49 | 0.92 | 9.18 | 745,817 | -15.45 | -81.75% |
Omeros Description
| Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. |
